Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells

被引:88
作者
Fagerli, Unn-Merete [1 ,5 ]
Holt, Randi U. [1 ,7 ]
Holien, Toril [1 ]
Vaatsveen, Thea K. [1 ]
Zhan, Fenghuang [2 ]
Egeberg, Kjartan W. [1 ]
Barlogie, Bart [2 ]
Waage, Anders [1 ,6 ]
Aarset, Harald [4 ]
Dai, Hong Yan [1 ,4 ]
Shaughnessy, John D., Jr. [2 ]
Sundan, Anders [1 ]
Borset, Magne [1 ,3 ]
机构
[1] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7489 Trondheim, Norway
[2] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
[3] St Olavs Univ Hosp, Dept Immunol & Transfus Med, Trondheim, Norway
[4] St Olavs Univ Hosp, Dept Pathol & Mol Genet, Trondheim, Norway
[5] St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway
[6] St Olavs Univ Hosp, Dept Hematol, Trondheim, Norway
[7] Sor Trondelag Univ Coll, Fac Technol, Trondheim, Norway
关键词
D O I
10.1182/blood-2007-07-101139
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma (MM) is characterized by accumulation and dissemination of malignant plasma cells (PCs) in the bone marrow (BM). Gene expression profiling of 2 MM cell lines (OH-2 and IH-1) indicated that expression of PRL-3, a metastasis-associated tyrosine phosphatase, was induced by several mitogenic cytokines. Cytokine-driven PRL-3 expression could be shown in several myeloma cell lines at both the mRNA and protein levels. There was significantly higher expression of the PRL-3 gene in PCs from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), and myeloma than in PCs from healthy persons. Among 7 MM subgroups identified by unsupervised hierarchical cluster analysis, PRL-3 gene expression was significantly higher in the 3 groups denoted as "proliferation," "low bone disease," and "MMSET/FGFR3.," PRL-3 protein was detected in 18 of 20 BM biopsies from patients with MM. Silencing of the PRL-3 gene by siRNA reduced cell migration in the MM cell line INA-6, but had no detectable effect on proliferation and cell-cycle phase distribution of the cells. In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells.
引用
收藏
页码:806 / 815
页数:10
相关论文
共 56 条
[11]  
Buffart TE, 2005, CELL ONCOL, V27, P57
[12]   Rho and Rac take center stage [J].
Burridge, K ;
Wennerberg, K .
CELL, 2004, 116 (02) :167-179
[13]   Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8 [J].
Carbone, A ;
Cilia, AM ;
Gloghini, A ;
Capello, D ;
Todesco, M ;
Quattrone, S ;
Volpe, R ;
Gaidano, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (04) :1081-1089
[14]   Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells [J].
Croonquist, PA ;
Linden, MA ;
Zhao, FY ;
Van Ness, BG .
BLOOD, 2003, 102 (07) :2581-2592
[15]   PRL-1, A UNIQUE NUCLEAR-PROTEIN TYROSINE PHOSPHATASE, AFFECTS CELL-GROWTH [J].
DIAMOND, RH ;
CRESSMAN, DE ;
LAZ, TM ;
ABRAMS, CS ;
TAUB, R .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (06) :3752-3762
[16]   Rho GTPases in cell biology [J].
Etienne-Manneville, S ;
Hall, A .
NATURE, 2002, 420 (6916) :629-635
[17]   PRL tyrosine phosphatases regulate Rho family GTPases to promote invasion and motility [J].
Fiordalisi, JJ ;
Keller, PJ ;
Cox, AD .
CANCER RESEARCH, 2006, 66 (06) :3153-3161
[18]   Catalytic domain of PRL-3 plays an essential role in tumor metastasis - Formation of PRL-3 tumors inside the blood vessels [J].
Guo, K ;
Li, J ;
Tang, JP ;
Koh, V ;
Gan, BQ ;
Zeng, Q .
CANCER BIOLOGY & THERAPY, 2004, 3 (10) :945-951
[19]   Advances in biology of multiple myeloma: clinical applications [J].
Hideshima, T ;
Bergsagel, PL ;
Kuehl, WM ;
Anderson, KC .
BLOOD, 2004, 104 (03) :607-618
[20]   Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells [J].
Hjertner, Ö ;
Hjorth-Hansen, H ;
Börset, M ;
Seidel, C ;
Waage, A ;
Sundan, A .
BLOOD, 2001, 97 (02) :516-522